OOIR: Observatory of International Research

Papers

(The H4-Index of Haematologica is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
The polymerase chain reaction, so simple, so clever: the discovery that made minimal residual disease come true	161
Bence Jones Island in Shepherd Bay, Nunavut: a little known tribute to the legendary physician and chemist’s “thé de voyage”	115
Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma	105
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection	91
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients	90
BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?	78
Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice	67
Investigating the influence of germline <i>ATM</i> variants in chronic lymphocytic leukemia on cancer vulnerability	66
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy	59
CD47 expression in acute myeloid leukemia varies according to genotype	57
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation	53
The first human acute myeloid leukemia genome ever fully sequenced	52
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the CONS	49
Acute myeloid leukemia at first relapse: approaching the precipice	46
Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells	45
Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel	45
Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis	44
“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms	43
Comprehensive characterization of human bone marrow microenvironment shows age-related changes	43
Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms	43
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response	42
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program	41
An unusual case of thalassemia intermedia with inheritable complex repeats detected by single-molecule optical mapping	41
Full <I>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis	40
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma	39

Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies	39
Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade	39
Specific inhibition of the transporter MRP4/ABCC4 affects multiple signaling pathways and thrombus formation in human platelets	38
Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers	37
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma	37
Asparaginase-associated hyperammonemia	37
PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia	35
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma	35
A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials	35
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies	34
Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, metaanalysis, and call to action	34
Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells	34
Acute lymphoblastic leukemia cells are able to infiltrate the brain subventricular zone stem cell niche and impair neurogenesis	34